Drug · DIN 02492075
SSP+
BUFFY COAT OR APHERESIS PREPARATION
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since December 18, 2022; first marketed December 18, 2022.
- Drug Identification Number (DIN)
- 02492075
- Company (DIN owner)
- Maco PharmaMouvaux, Nord-Pas-De-Calais, France
- Schedule
- Ethical
- Dosage form
- Solution
- Route
- Intravenous
- Therapeutic class (ATC)
- Blood transfusion, auxiliary products V07AC
- Class
- Human
- Record last updated
- August 26, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| SODIUM CHLORIDE | 4.05 G | L |
| POTASSIUM CHLORIDE | 0.37 G | L |
| MAGNESIUM CHLORIDE | 0.3 G | L |
| SODIUM CITRATE | 3.18 G | L |
| SODIUM PHOSPHATE MONOBASIC | 1.05 G | L |
| DISODIUM PHOSPHATE | 3.05 G | L |
| SODIUM ACETATE | 4.42 G | L |
Notices of Compliance
Health Canada approvals that name this DIN.
- September 19, 2019: NOC 22757New Drug Submission (NDS)
Other DINs named SSP+
- DIN 02492067 · Marketed